



TRUVEN[≡]
HEALTH ANALYTICS

TRUVEN HEALTH ANALYTICS

MICROMEDEX SOLUTIONS

May 2017

碩睿資訊有限公司
Shou Ray Information Service Co., Ltd

Outline

What Is Micromedex?


Databases: 5 Topics included

Navigation & Searching

Case Study: Clinical approach

What Is Micromedex ?

◆ Micromedex[®] Solutions Healthcare Series





Why they trust Micromedex ?

◆ Authority

- ◆ DrugDex, Poisindex, DiseaseDex Emergency Medicine was adapted by **U.S, Department of State** as official medical encyclopedia

◆ Quality

- ◆ Strict editorial process

◆ Reliability

- ◆ Provide service for schools, hospitals , and pharmaceutical companies over 30 years

◆ Consistency

- ◆ Consistency formats and standards

◆ Full-text databases

- ◆ Fully referenced, Peer reviewed, Written by clinicians

Drug Information	Disease Information
<p><u>DRUGDEX[®] System</u> <u>DRUG-REAX[®] System</u> <u>MARTINDALE</u> <u>Index Nominum</u> <u>Physicians' Desk Reference[®](PDR[®])</u> <u>P & T QUIK[®] Reports</u> <u>IV INDEX[®] System</u> <u>MSDS</u> <u>IDENTIDEX[®] System</u> <u>Red Book[®] Online</u> <u>KINETIDEX[®] System</u></p>	<p><u>DISEASEDEX[™] General Medicine</u> <u>DISEASEDEX[™] Emergency Med.</u> <u>Lab adviser[™]</u></p> <p>Patient Education</p> <p><u>AltCareDex[®] Alternative Medicine Education</u> <u>CareNotes[™] System</u></p> <p>Toxicology Information</p> <p><u>POISINDEX[®] System</u> <u>TOMES[®] System</u> <u>REPRORISK[®] System</u></p>
Alternative Medicine	Free Resources
<p><u>AltMedDex[®] System</u> <u>AltMedDex[®] Protocols</u> <u>Herbal Medicines</u></p>	<p><u>Calculators</u> <u>mobileMICROMEDEX[™] System</u></p>

主頁

藥物
相互作用

IV 相容性

藥物
鑒定

藥物
比較

CareNotes®

NeoFax® / Pediatrics

其他工具 ▾

3. 小幫手區

全部

藥物

疾病

毒理學

搜尋藥物、疾病、毒理學及其他資訊

1. 檢索區

搜尋 Micromedex



4



最新消息

- Type 2 Diabetes Combination Approved
- Expanded Approval of Vyvanse(R) for...
- Combination Treatment Approved for HIV-1
- New HIV Combination Drug Approved
- New Hemodialysis Iron Replacement

Read Top News



5



支援和訓練

- Citing Micromedex
- Clinical Consulting & Services
- Integrated Content Options for MU & More
- Tips & Tricks
- Training & Tutorials
- User Guide

Support Request



6



資源

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS



Download Mobile Apps

我的訂閱

我的訂閱 | 開道 | Training Center | 說明 | 下載中心 | 登出

已經訂購

尚未訂購

用於 Shou Ray Informa Service Co Ltd. (客戶號： 418410001)

Your Subscribed Products	Non-subscribed Products
MICROMEDEX <ul style="list-style-type: none">AAPCC Codes in POISINDEX®Alternative MedicineDetailed Drug Information for the ConsumerDISEASEDEX™ Emergency MedicineDISEASEDEX™ General MedicineDRUGDEX® SystemImprint Codes in Identidex®Index NominumInteraction CheckingItalian Drug DatabaseIV CompatibilityLab Advisor™MARTINDALEMSDS from USP	MICROMEDEX <ul style="list-style-type: none">PharmacyXpert






列印 關閉

MICROMEDEX® 訂閱



用於 Mennonite Christian Hospital (客戶號：632650001)

Your Subscribed Products

MICROMEDEX

-  Alternative Medicine
-  DRUGDEX® System
-  Imprint Codes in Identidex®
-  Interaction Checking
-  IV Compatibility


















補充用藥：

-  Calculators
-  mobileMicromedex

外部應用：

Non-subscribed Products





MICROMEDEX

-  AAPCC Codes in POISINDEX®
-  Detailed Drug Information for the Consumer
-  DISEASEDEX™ Emergency Medicine
-  DISEASEDEX™ General Medicine
-  Index Nominum
-  Italian Drug Database
-  Lab Advisor™
-  MARTINDALE
-  MSDS from USP
-  P&T QUIK® Reports
-  PDR®
-  POISINDEX® Managements
-  POISINDEX® System
-  RED BOOK Online®
-  REPRORISK® System
-  TOMES® System
-  United Kingdom Drug Information

補充用藥：

N/A

外部應用：

-  CareNotes®
-  Formulary Advisor®
-  NeoFax®
-  Pediatrics

資料庫登入方式

- 限IP範圍內
 - 有同時上線人數限制
- 利用行動載具下載APP版本
 - 離線版，需定期更新

使用說明(Help)

每次用完之後
請點選登出按鈕



主頁	藥物 相互作用	IV 相容性	藥物 鑒定	藥物 比較	CareNotes®	NeoFax® / Pediatrics	其他工具 ▾
----	------------	--------	----------	----------	------------	----------------------	--------

全部 藥物 疾病 毒理學

搜尋藥物、疾病、毒理學及其他資訊

搜尋 Micromedex 

 最新消息 <ul style="list-style-type: none">Type 2 Diabetes Combination ApprovedExpanded Approval of Vyvanse(R) for...Combination Treatment Approved for HIV-1New HIV Combination Drug ApprovedNew Hemodialysis Iron Replacement	 支援和訓練 <ul style="list-style-type: none">Citing MicromedexClinical Consulting & ServicesIntegrated Content Options for MU & MoreTips & TricksTraining & TutorialsUser Guide	 資源 <ul style="list-style-type: none">黑框警告Comparative TablesDo Not Confuse Drug ListDrug ClassesDrug ConsultsREMS
---	---	---

免費下載APP

全部 | 藥物 | 疾病 | 毒理學

搜尋藥物、疾病、毒理學及其他資訊

搜尋 Micromedex



最新消息

- 12-Hour Codeine-Based Cough...
- Once-Daily Inhaler Now for Asthma
- First Spray-Dried Fibrin Sealant...
- New Hemodialysis Iron Replacement

Read Top News



支援和訓練

- Citing Micromedex
- Clinical Consulting & Services
- Integrated Content Options for MU & More
- Tips & Tricks
- Training & Tutorials
- User Guide

Support Request




資源

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS



Download Mobile Apps

APP下載



- 可離線使用，不受制於使用人數

Drug Reference



Drug Interactions



IV Compatibility




手機平板下載方式

Micromedex Apps on Apple® Devices

Micromedex Apps on Apple®, Android® and Windows 8® Devices

Free Micromedex® Drug Reference for Internet Subscribers



- The **Free Micromedex Drug Reference for Internet Subscribers** app for Apple, Android, and Windows 8 devices is available for FREE for Micromedex customers.
- You can access these apps via the iTunes® App Store (Apple devices), Google Play® (Android devices) or the Windows Store® (Windows 8 devices).
- Android users only: the app is called **Free Micromedex Drug Reference** in the Google Play store.
- You can activate the app by following the simple instructions below.

Simple instructions for installation:

- Step 1** Visit the iTunes App Store (Apple devices), Google Play Store (Android devices) or the Windows Store (Windows 8 devices) and search for "Micromedex."
- Step 2** From all the Micromedex app results, select **Free Micromedex Drug Reference for Internet Subscribers** (Apple devices and Windows 8 devices) or **Free Micromedex Drug Reference** (Android devices). You may be prompted to enter your Apple, Google or Windows ID.
- Step 3** The app should download directly to your device. (If you visited the iTunes App Store on your PC rather than your device, you may have to sync your device to iTunes on your PC, in order to load the app onto your device.)
- Step 4** Open the app on your device. Enter the password [redacted] to begin using **Free Micromedex Drug Reference for Internet Subscribers**. *The password is case sensitive. Please enter it exactly as it appears here.*

Drug Reference & Drug Interactions:2ANeze
IV Compatibility:pepR7P

This app is free only for clinicians ("subscribers") who work at a hospital or facility with an online subscription to Micromedex Solutions products. Subscribers can obtain their password by signing into the Micromedex Solution product and following the "Download Mobile Apps" link under the Resources tab or by simply contacting our Support Center.

The password only needs to be entered once per year.

Need Help? Not sure if you work at a hospital or facility that subscribes to Micromedex Solutions?

Can't find the link to the password?

Visit Our Support Center:

www.micromedex.com/mobile

Once you've obtained your password, please enter it below:

Continue

Your password has expired. Please provide a current password to continue.



Interactions

aspi

Drug List Selected Drugs

Aspirin	✓
Aspirin/Butalbital/Caffeine	+
Aspirin/Caffeine/Dihydrocodeine Bitartrate	+
Aspirin/Codeine Phosphate	+
Aspirin/Dipyridamole	+
Aspirin/Omeprazole	+
Aspirin/Oxycodone Hydrochloride	+
Aspirin/Pravastatin Sodium	+
Aspirin (Aspirin)	+
Aggrenox (Aspirin/Dipyridamole)	+
Anacin Aspirin Free (Acetaminophen)	+
Ascomp w/Codeine (Butalbital/Aspirin/Caffeine/Codeine Phosphate)	+



Interactions

Drug List Selected Drugs

- Warfarin Sodium
- Aspirin

Clear All View Interactions



Interactions



✓ Major

Ⓢ Warfarin Sodium : Aspirin



Interactions

Warfarin Sodium : Aspirin

Severity: Major

Onset: Not Specified

Documentation: Fair

Interaction Effect:

Concurrent use of WARFARIN and ANTIPLATELET AGENTS may result in increased risk of bleeding.

Clinical Management:

Coadministration of warfarin and antiplatelet agents may increase the risk of bleeding. Monitor patients closely for signs or symptoms of bleeding (Prod Info Jantoven(R) oral tablets, 2014) and evaluate promptly. Lab monitoring may be appropriate.

Probable Mechanism:
additive effects

最新消息

最新消息

- Zecuity(R) Patch May Cause Burns and...
- Cholera Vaccine Approved
- Imodium(R) Causes Heart Problems
- Bleeding with Aspirin-containing...
- Byvalson(TM) Approved to Treat...

Read Top News



Latest News

關閉 X Apps

▼ Zecuity(R) Patch May Cause Burns and Scarring

On June 2, 2016, the US FDA announced that it is investigating a possible correlation between use of the migraine patch Zecuity(R) (sumatriptan iontophoretic) transdermal system and the risk of serious burns and permanent scarring. Since the product was first marketed in September 2015, many patients have reported suffering blistering, cracking, discoloring, and pain in areas where the patch was worn.

On June 10, 2016, Teva Pharmaceuticals announced that it would temporarily discontinue Zecuity sales and distribution pending results of the FDA investigation.

Healthcare professionals are urged to discontinue prescribing the Zecuity patch. If a patient experiences moderate to severe treatment-site pain, healthcare professionals should encourage them to remove the patch immediately and contact their doctor for an alternative treatment.

An important prescribing update can be found at <http://www.fda.gov/downloads/Drugs/DrugSafety/UCM506332.pdf>.

Last modified: 06/13/2016 12:57:48

Full Article

- ▶ Cholera Vaccine Approved
- ▶ Imodium(R) Causes Heart Problems
- ▶ Bleeding with Aspirin-containing Antacids
- ▶ Byvalson(TM) Approved to Treat Hypertension

支援和訓練

- Citing Micromedex
- Clinical Consulting & Services
- Integrated Content Options for MU & More
- Product User Tips & Quick Answers
- Training Center
- User Guide

資源

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS

Citing Micromedex



最新消息

- 12-Hour Codeine-Based Cough...
- Once-Daily Inhaler Now for Asthma
- First Spray-Dried Fibrin Sealant...
- New Hemodialysis Iron Replacement



支援和訓練

- **Citing Micromedex**
- Clinical Consulting & Services
- Integrated Content Options for MU & More
- Tips & Tricks
- Training & Tutorials
- User Guide



資源

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS



An entire System or Database:

[↑ Top of page](#)

AltCareDex® System:

AltCareDex® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> (cited: *month/day/year*).

AltMedDex® System:

AltMedDex® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> (cited: *month/day/year*).

AltMed-REAX™ for the Patient:

AltMed-REAX™ for the Patient (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> (cited: *month/day/year*).

CareNotes® System:

CareNotes® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> (cited: *month/day/year*).



Citing Micromedex

HOW TO REFERENCE THE Truven Health Analytics SYSTEMS

An individual document:

DRUGDEX® System:

(Title). In: DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> (cited: *month/day/year*).

AltCareDex® System:

(Title). In: AltCareDex® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> (cited: *month/day/year*).

AltMedDex® System:

(Title). In: AltMedDex® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> (cited: *month/day/year*).

AltMed-REAX™ for the Patient:

(Title). In: AltMed-REAX™ for the Patient (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> (cited: *month/day/year*).

DISEASEDEX™ Emergency Medicine:

DISEASEDEX™ Emergency Medicine. In: DISEASEDEX - Emergency Medicine (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> (cited: *month/day/year*).

DISEASEDEX™ General Medicine:

(Title). In: DISEASEDEX - General Medicine (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> (cited: *month/day/year*).

Dosing & Therapeutic Tools Database:

Anon: Cephalosporin Generations. In: Dosing & Therapeutic Tools Database (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> (cited: *month/day/year*).

DRUGDEX® System:

(Title). In: DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com/> (cited: *month/day/year*).



支援和訓練


- Citing Micromedex
- Clinical Consulting & Services
- Integrated Content Options for MU &
- **Tips & Tricks**
- Training & Tutorials
- User Guide

Micromedex Tips & Tricks



To help you get the most out of your Micromedex® Clinical Knowledge subscription, use this as a quick reminder of some of the helpful and relevant information available at your fingertips.

Simply type the term or phrase shown in the left column below into the search field, then click the SEARCH button.



Support Request

Search Term/Phrase	Description
2015	Returns the Drug Consults, New Drug Approvals - 2015 Micromedex News and Childhood Immunization Schedule - United States 2015 . The immunization schedule is based on recommendations from the U.S. Centers for Disease Control and Prevention.*
Abbreviations	Returns the Drug Consult, Abbreviations , which provides definitions for abbreviations used commonly throughout Micromedex content.*
BBW (or Black Box) ✕	Returns a list of drugs that carry a black-box warning. Selecting a drug link opens the black-box warning content.
Causes of [Disease/Condition]	Returns links to the Disease Summary Dashboards, and to the Medical History or Etiology/ Pathophysiology sections in disease reviews.* Example: <i>causes of anemia</i>
Chemotherapy	Returns various Drug Consults, such as the Chemotherapy Acronyms and Dosing , Chemotherapy Dosing in Obese Adults , Chemotherapy and Radiotherapy Protectants - ASCO Clinical Practice Guidelines , and Chemotherapy and Radiotherapy Treatment Guidelines for Nausea and Vomiting .*
Clinical Approach To	Click on the Toxicology Results link to see toxin-induced disease states (hyperthermia, hypotension, metabolic acidosis, or tachyarrhythmia).*
Comparative Table ✕	Returns lists of comparative drug class tables.

搭配專業術語查詢

主頁

藥物
相互作用

IV 相容性

藥物
鑒定

藥物
比較

CareNotes®

NeoFax® / Pediatrics

其他工具 ▾

全部

藥物

疾病

毒

用來治療暈厥的藥

搜尋藥物、疾病、毒理學及其他資訊

Drugs that treat Syncope

Syncope

Drugs that treat Syncope

Drugs that cause Syncope

Syncope and collapse

Syncope attack

Drugs that treat Syncope attack

Drugs that cause Syncope attack

最新消息

- Once-Daily COPD Inhaler
- Dosing Errors with Zerbaxa(TM)...
- Now Live. New Enhancements to...
- Attending MUSE 2015? Start Here
- Get the Facts: Hospital Performance

- tips & tricks
- Training & Tutorials
- User Guide

- Drug Classes
- Drug Consults
- REMS

用來治療暈厥的藥

drugs that treat syncope



主頁

藥物
相互作用

IV 相容性

藥物
鑒定

藥物
比較

CareNotes®

NeoFax® / Pediatrics

其他工具 ▾

列印

Drugs That Treat Syncope

顯示：[Effective \(0\)](#) | [Evidence Favors Efficacy \(6\)](#) | [Evidence is Inconclusive \(0\)](#) | [Ineffective \(0\)](#) | [Not Rated \(0\)](#)

Displaying 6 results for "Drugs That Treat Syncope"

▶ [Effective \(0 results\)](#)

▶ [Evidence Favors Efficacy \(6 results\)](#)

▶ [Evidence is Inconclusive \(0 results\)](#)

▶ [Ineffective \(0 results\)](#)

▶ [Not Rated \(0 results\)](#)

1. 有效
2. 有證據支持有效性
3. 證據支持是不確定
4. 無效
5. 沒評級

Displaying 6 results for "Drugs That Treat Syncope"

▶ Effective (0 results)

▼ Evidence Favors Efficacy (6 results)

藥物名稱	Indication	年齡組別
Acebutolol Hydrochloride	Syncope	Adult
Enalapril Maleate	Neurally-mediated syncope	Adult
Epinephrine	<u>Syncope, Due to complete heart block or carotid sinus hypersensitivity</u>	Adult
Midodrine Hydrochloride	Syncope	Adult
Nitroglycerin	Provocative test - Vasovagal syncope	Adult
Pindolol	Syncope	Adult

串聯至劑量 “adult dosing”

Epinephrine

Drug Classes: [Adrenergic](#) | [Alkylarylamine](#) | [All](#)

Routes: [Epidural](#) | [Inhalation](#) | [Injection](#) | [Intramuscular](#) | [Intravenous](#) | [Nasal](#)

簡要解答

深入解答

全部結果

Dosing/Administration

Adult Dosing

[Pediatric Dosing](#)

[FDA Uses](#)

[Non-FDA Uses](#)

[Dose Adjustments](#)

[Administration](#)

[Comparative Efficacy](#)

[Place In Therapy](#)

Medication Safety

[Contraindications](#)

[Precautions](#)

[Adverse Effects](#)

Dosing/Administration



Adult Dosing

請參閱 [深入解答](#) 瞭解詳細結果。

- Anaphylaxis: (Auto-injector) Inject contents of 0.3-mg prefilled syringe IM or SUBQ; may repeat with an additional auto-injector if severe anaphylaxis persists [3][4]
- Anaphylaxis: (Injectable solution) 0.2 to 0.5 mg (0.2 to 0.5 mL of a 1:1000 solution) IM or SUBQ every 5 minutes as needed (guideline dosing) [5] OR 0.2 to 1 mg SUBQ (manufacturer dosing) [6]
- Anaphylaxis: (IV infusion) 1 mg (1 mL of 1:1000 solution) in 250 mL D5W (4 mcg/mL) and infuse IV at a rate of 1 mcg/min (15 mL/hr) to 10 mcg/min OR epinephrine 1 mg (1 mL of 1:1000 solution in 100 mL of NS (10 mcg/mL)) and infuse IV at an initial rate of 5 to 15 mcg/min (30 to 100 mL/hr) (guideline dosing) [5]
- Asthma: (injectable solution) 0.2 to 1 mg (0.2 to 1 mL of 1:1000 solution) SUBQ [6]
- Asthma: (inhalation) start with 1 inhalation (0.22 mg); if symptoms not relieved after at least 1 min, use once more; do not use again for at least 3 hr [7]
- Local anesthesia; Adjunct: (intraspinal) 0.2 to 0.4 mg added to anesthetic spinal fluid mixture [13]
- Local anesthesia; Adjunct - Obstetric procedure: 0.2 mg added to bupivacaine for hyperbaric spinal anesthesia for cesarean section (study dosing) [14]
- Syncope, Due to complete heart block or carotid sinus hypersensitivity: 0.2 to 1 mg (0.2 to 1 mL of 1:1000 solution) subQ or IM [6]

相關結果

[毒理學](#)

[疾病](#)

[Drug Availability](#)

[Drug Consults](#)

[eMC SmPC \(UK\)](#)

[Index Nominum](#)

[IT- Dialogo Sui Farmaci](#)

[Martindale](#)

[PDR®](#)

[Product Lookup - Martindale](#)

[Product Lookup - RED Book Online](#)

[Product Lookup - Tox & Drug](#)

[消費者藥物資訊](#)

Comparative Tables

Dosage

Class

▶ BENZODIAZEPINES (SELECTED)

▶ CORTICOSTEROIDS (SELECTED) PROPERTIES AND POTENCIES

▶ NSAID (NONSTEROIDAL ANTIINFLAMMATORY AGENTS (SELECTED))

☰ 資源

- 黑框警告
- **Comparative Tables**
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS

針對各廠牌的藥品，列出各種適應症及有效劑量範圍

Oral NSAIDs

▶ PP

Generic Name	Brand Name (US)	Indications	Effective Dosage Range
Diclofenac	Cataflam (diclofenac potassium immediate-release tablets)	Pain	50 mg 3 times daily
		Dysmenorrhea	50 mg 3 times daily
		Osteoarthritis	50 mg 2 to 3 times daily
		Rheumatoid Arthritis	50 mg 3 to 4 times daily
Voltaren (diclofenac sodium enteric-coated tablets)	Voltaren (diclofenac sodium enteric-coated tablets)	Ankylosing Spondylitis	25 mg 4 times daily, with an extra 25 mg at bedtime if needed
		Osteoarthritis, Rheumatoid Arthritis	50 mg 2 to 3 times daily, or 75 mg twice daily
Voltaren XR (diclofenac sodium extended-release tablets)	Voltaren XR (diclofenac sodium extended-release tablets)	Osteoarthritis	100 mg every day
		Rheumatoid Arthritis	75 to 100 mg once or twice daily

Comparative Tables

Dosage

Class

▶ ACE INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS (SELECTED)

▶ ANTIDIABETIC AGENTS (SELECTED)

▶ BETA BLOCKERS

資源

- 黑框警告
- Comparative Tables
- Do Not Confuse Drug List
- Drug Classes
- Drug Consults
- REMS

針對各廠牌藥品，列出常用劑量範圍、最大劑量、低血糖風險、重量變化、胃腸症狀

Generic Drug Name And Brand Name	Usual Dosage Range*	Maximum Daily Dose	Drug Class	Hypoglycemia Risk**	Weight Change**	GI Symptoms**
Acarbose (Precose(R))	25 to 100 mg ORALLY 3 times daily with meals	60 kg or less: 150 mg; Greater than 60 kg: 300 mg	AGI	not significant	not significant	diarrhea, flatulence
Alogliptin (Nesina(R))	25 mg ORALLY once daily	---	DPP-4 inhibitor	not significant	not significant	not significant
Alogliptin Benzoate/Metformin (Kazano)	alogliptin 12.5 mg/metformin 500 mg to alogliptin 12.5 mg/metformin 1000 mg ORALLY twice daily with meals	alogliptin 25 mg/metformin 2000 mg	DPP-4 inhibitor /Biguanide	***	***	***
Alogliptin/Pioglitazone(Oseni)	alogliptin 25 mg/pioglitazone 15 mg to alogliptin 25 mg/pioglitazone 45 mg ORALLY once daily	alogliptin 25 mg/pioglitazone 45 mg	DPP-4 inhibitor/ TZD	***	***	***

實作時間

- 在Micromedex資料庫中，如何查找單一藥物交互作用列表與IV 相容性列表？(以**PHENYTOIN**為例：一種治療「癲癇」的藥物。)

臨床用途

phenytoin



Phenytoin

Dosing **Phenytoin**

Adverse Effects **Phenytoin**

Indications **Phenytoin**

Interactions **Phenytoin**

Phenytoin Capsules BP 2016

Phenytoin Chewable Tablets USP 39

Phenytoin Injection BP 2016

Phenytoin measurement

Phenytoin

Substance

Drug Classes: Anticonvulsant | Central Nervous System Agent | All

Phenytoin

Routes: Oral

Quick Answers

In-Depth Answers

All Results

Dosing/Administration

- Adult Dosing
- Pediatric Dosing
- FDA Uses
- Non-FDA Uses
- Dose Adjustments
- Administration
- Comparative Efficacy
- Place In Therapy

Medication Safety

- Contraindications
- Precautions
- Adverse Effects
- Black Box Warning
- REMS
- Drug Interactions (single)**
- IV Compatibility (single)
- Pregnancy & Lactation
- Monitoring
- Do Not Confuse

Mechanism of Action

Mechanism of Action

Pharmacokinetics

Pharmacokinetics

Patient Education

- Medication Counseling
- Patient Handouts

Toxicology

- Clinical Effects
- Range of Toxicity
- Treatment

Medication Safety

Drug Interactions (single)

See 'In-Depth Answers' for detailed results.

View multiple drug interactions

Refine by: Severity: All Documentation: All

Check/uncheck to refine severity setting(s).

Check all | Uncheck all

- Contraindicated
- Major
- Moderate
- Minor
- Unknown

Cancel Update

Check/uncheck to refine documentation setting(s).

Check all | Uncheck all

- Excellent
- Good
- Fair
- Unknown

Cancel Update

LURASIDONE -- STRONG CYP3A4 INDUCERS	Contraindicated	Good	Concurrent use of LURASIDONE and STRONG CYP3A4 INDUCERS may result in decreased lurasidone exposure.
PHENYTOIN -- TELAPREVIR	Contraindicated	Good	Concurrent use of PHENYTOIN and TELAPREVIR may result in reduced telaprevir plasma concentrations and potential loss of efficacy.
ARTEMETHER/LUMEFANTRINE -- PHENYTOIN	Contraindicated	Fair	Concurrent use of ARTEMETHER/LUMEFANTRINE and PHENYTOIN may result in decreased artemether/lumefantrine exposure and loss of efficacy.
DASABUVIR -- SELECTED ANTICONVULSANTS	Contraindicated	Fair	Concurrent use of DASABUVIR and SELECTED ANTICONVULSANTS may result in decreased dasabuvir exposure.
DACLATASVIR -- STRONG CYP3A4 INDUCERS	Contraindicated	Fair	Concurrent use of DACLATASVIR and STRONG CYP3A4 INDUCERS may result in decreased daclatasvir exposure.

Print

Related Results

Alternative Medicine
Disease
Toxicology

Drug Consults
Product Lookup - Tox & Drug

Drug Interactions (single)



Dosing/Administration

- Adult Dosing
- Pediatric Dosing
- FDA Uses
- Non-FDA Uses
- Dose Adjustments
- Administration
- Comparative Efficacy
- Place In Therapy

Medication Safety

- Contraindications
- Precautions
- Adverse Effects
- Black Box Warning
- REMS
- Drug Interactions (single)
- IV Compatibility (single)**
- Pregnancy & Lactation
- Monitoring
- Do Not Confuse

Medication Safety

IV Compatibility (single)

Drugs

Solutions

Drugs

Phenytoin
Phenytoin Sodium

Phenytoin

Amikacin
Aminophylline
Bleomycin Sulfate
Brevitium
Cephalothin
Cephapirin
Chloramphenicol
Cimetidine
Clindamycin
Codeine Phosphate
Cyanocobalamin
Dimenhydrinate
Diphenhydramine
Dobutamine
Enalaprilat
Erythromycin Gluceptat
Esmolol
Famotidine
Fat Emulsion
Fluconazole
Foscarnet
Gentamicin
Heparin

Solutions

Dextrose 5% in lactated Ringer's injection
Dextrose 5% in sodium chloride 0.9%
Dextrose 5% in water
Sodium chloride 0.45%
Sodium chloride 0.9%

Dextrose 5% in lactated Ringer's injection

1) Incompatible

a) Dextrose 5% in lactated Ringer's injection (with phenytoin 1 g/L in a polyvinylchloride container, visible crystal formation reported within 6 to 9 hours which coincided with a reduction in the phenytoin concentration of 0.8% in 8 hours and 7% in 24 hours; no temperature specified) [1724]; (with phenytoin 4.6, 9.2 or 18.4 g/L, crystal formation reported; large variation in phenytoin concentration was reported in solution which was delivered through a 0.22 micron filter over a 24 hour period at 29 degrees C) [1725]; (with phenytoin 0.4, 0.98, 2.38, or 4.55 g/L, a variable degree of precipitate formation was reported, depending upon the drug manufacturer, but no significant reduction in phenytoin concentration was reported in 12 to 24 hours at 23 degrees C) [1726]

Dextrose 5% in sodium chloride 0.9%

1) Incompatible

a) Dextrose 5% in sodium chloride 0.9% (with phenytoin 1 g/L in a polyvinylchloride container, visible crystal formation reported within minutes with crystallization of 21% of the phenytoin within 8 hours and 38% within 24 hours) [1724]

b) Phenytoin 1 g/L in Dextrose 5% in sodium chloride 0.9% in a polyvinylchloride container, visible crystal formation reported within minutes with crystallization of 21% of the phenytoin within 8 hours and 38% within 24 hours [1727]

Dextrose 5% in water

1) Incompatible

a) Dextrose 5% in water (with phenytoin 1 g/L in a polyvinylchloride container, visible crystal formation reported within minutes with crystallization of 15% of the phenytoin within 8 hours and 36% within 24 hours) [1724]; (with phenytoin 4.6, 9.2 or 18.4 g/L, crystal formation reported; large variation in phenytoin concentration was reported in solution which was delivered through a 0.22 micron filter over a 24 hour period at 29 degrees C) [1725]; (with phenytoin 1 g/L, crystalline precipitate formation reported within 24 hours at 25 degrees with 15% reduction of phenytoin concentration in solution; no visible precipitate or reduction of phenytoin concentration reported in 8 hours at 25 degrees C) [1728]; (with phenytoin 1 g/L, filtration of solution through 0.22 micron or 0.45 micron in-line filter

[View Full Document](#)

[Print](#)

Related Results

[Alternative Medicine
Disease
Toxicology](#)

[Drug Consults
Product Lookup - Tox & Drug](#)

Phenytoin

Drug Classes: [Anticonvulsant](#) | [Central Nervous System Agent](#) | [All](#)

Routes: **Oral**

Substance

Phenytoin

Regulatory Authority

 FDA

- Quick Answers
- In-Depth Answers**
- All Results

1 of 43 results for **ceph**

Dosing/Administration

Adult Dosing

Normal Dosage

Important Note

) There is approximately an equal amount of phenytoin in the free acid form and the sodium salt. Dose adjustment and serum level monitoring may be necessary when switching between products formulated with the free acid form and the sodium salt, and vice versa [1].


) Beers Criteria: Use caution in older adults [2].

Important Note

) There is approximately an equal amount of phenytoin in the free acid form and the sodium salt. Dose adjustment and serum level monitoring may be necessary when switching between products formulated with the free acid form and the sodium salt, and vice versa [77].

) Beers Criteria: Use caution in older adults [2].

- Dosing/Administration
- Dosing/Administration**
- Adult Dosing
- Pediatric Dosing
- FDA Uses
- Non-FDA Uses
- Dose Adjustments
- Administration
- Comparative Efficacy
- Place In Therapy
- Medication Safety
- Contraindications
- Precautions
- Adverse Effects
- Black Box Warning
- REMS
- Drug Interactions (single)
- IV Compatibility (single)
- Pregnancy & Lactation
- Monitoring
- Do Not Confuse

 [View Document Sections](#)

 [Print](#)

Phenytoin


Drug Classes: [Anticonvulsant](#) | [Central Nervous System Agent](#) | [All](#)

Routes: [Oral](#)

Substance

Phenytoin ▼

Regulatory Authority

 FDA ▼

Quick Answers

In-Depth Answers

All Results

Amikacin



– Adult Dosing ▼

 [View Document Sections](#)

 [Print](#)

3 of 5 results for [amikacin](#) ▲ ▼

Amikacin

a) Incompatible

1) [Amikacin](#) 5 mg/L with phenytoin 250 mg/L, immediate precipitation reported [1669]

Aminophylline

a) Incompatible

1) Phenytoin reported incompatible with aminophylline; conditions not specified [1694]

2) Phenytoin 1 mL, reconstituted, with aminophylline 1 mL, reconstituted, both added to Sterile water for injection 5 mL, precipitate formation was reported within 2 hours; exact drug concentrations not specified [1695]

Bleomycin Sulfate

a) Compatible

1) Bleomycin sulfate 20 or 30 U/L with phenytoin 500 mg/L, visually compatible and bleomycin activity retained for 1 week at 4 degrees C in Sodium chloride 0.9%; phenytoin activity not tested [1690]

Bretylum

a) Incompatible

Solutions

Dextrose 5% in lactated Ringer's injection

Dextrose 5% in sodium chloride 0.9%

Dextrose 5% in water

Sodium chloride 0.45%

Sodium chloride 0.9%

Dextrose 5% in lactated Ringer's injection

1) Incompatible

a) Dextrose 5% in lactated Ringer's injection (with phenytoin 1 g/L in a polyvinylchloride container, visible crystal formation reported within 6 to 9 hours which coincided with a reduction in the phenytoin concentration of 0.8% in 8 hours and 7% in 24 hours; no temperature specified) [1724]; (with phenytoin 4.6, 9.2 or 18.4 g/L, crystal formation reported; large variation in phenytoin concentration was reported in solution which was delivered through a 0.22 micron filter over a 24 hour period at 29 degrees C) [1725]; (with phenytoin 0.4, 0.98, 2.38, or 4.55 g/L, a variable degree of precipitate formation was reported, depending upon the drug manufacturer, but no significant reduction in phenytoin concentration was reported in 12 to 24 hours at 23 degrees C) [1726]

Dextrose 5% in sodium chloride 0.9%

1) Incompatible

a) Dextrose 5% in sodium chloride 0.9% (with phenytoin 1 g/L in a polyvinylchloride container, visible crystal formation reported within minutes with crystallization of 21% of the phenytoin within 8 hours and 38% within 24 hours) [1724]

b) Phenytoin 1 g/L in Dextrose 5% in sodium chloride 0.9% in a polyvinylchloride container, visible crystal formation reported within minutes with crystallization of 21% of the phenytoin within 8 hours and 38% within 24 hours [1727]

Dextrose 5% in water

1) Incompatible

a) Dextrose 5% in water (with phenytoin 1 g/L in a polyvinylchloride container, visible crystal formation reported within minutes with crystallization of 15% of the phenytoin within 8 hours and 36% within 24 hours) [1724]; (with phenytoin 4.6, 9.2 or 18.4 g/L, crystal formation reported; large variation in phenytoin concentration was reported in solution which was delivered through a 0.22 micron filter over a 24 hour period at 29 degrees C) [1725]; (with phenytoin 1 g/L, crystalline precipitate formation reported within 24 hours at 25 degrees with 15% reduction of phenytoin concentration in solution; no visible precipitate or reduction of phenytoin concentration reported in 8 hours at 25 degrees C) [1728]; (with phenytoin 1 g/L, filtration of solution through 0.22 micron or 0.45 micron in-line filter

Substance

Phenytoin ▼

Regulatory Authority



FDA ▼

View Document Sections

Print

SELECT SECTIONS TO PRINT: ✕

- Medication Safety**
 - Contraindications
 - Precautions
 - Adverse Effects
 - Black Box Warning
 - REMS
 - Drug Interactions (single)
 - IV Compatibility (single)
 - Pregnancy & Lactation
 - Monitoring

Close

Print

Black Box Warning

REMS

Drug Interactions (single)

IV Compatibility (single)

Pregnancy & Lactation

Monitoring

Do Not Confuse

Mechanism of Action

Mechanism of Action

Pharmacokinetics

Pharmacokinetics

Patient Education

Medication Counseling

Patient Handouts

Toxicology

Clinical Effects

Range of Toxicity

Treatment

Patient Education

Patient Handouts

See ['Quick Answers'](#) for summary results.

A) Phenytoin (By injection) Phenytoin

Treats and prevents seizures.

When This Medicine Should Not Be Used:

This medicine is not right for everyone. You should not receive this medicine if you had an allergic reaction to phenytoin or similar medicines, or if you are pregnant or have certain heart rhythm problems.

How to Use This Medicine:

Injectable

This medicine is usually given only for a short time when you cannot take oral medicine, such as when you are in the hospital or when you have surgery.

A nurse or other health professional will give you this medicine. This medicine is given as a shot into a muscle or into a vein.

After your condition improves, your doctor might switch you to an oral medicine that works the same way. Talk to your doctor if you have any concerns about this.

Drugs and Foods to Avoid:

Ask your doctor or pharmacist before using any other medicine, including over-the-counter medicines, vitamins, and herbal products.

Do not use this medicine together with delavirdine.

The list below includes some of the medicines that can interact with phenytoin. There are many other drugs not listed. Make sure your doctor knows the names of all the medicines you use.

Tell your doctor if you are using St John's wort, albendazole, amiodarone, aspirin, chlordiazepoxide, cyclosporine, diazepam, diazoxide, digoxin, disulfiram, folic acid, furosemide, isoniazid, methylphenidate, nisoldipine, praziquantel, quinidine, reserpine, rifampin, theophylline, tolbutamide, or vitamin D.

Tell your doctor if you are using cancer medicine, birth control pills, medicine to treat an infection (including a sulfa drug, medicine to treat HIV/AIDS, or medicine for a fungus infection), a steroid medicine, medicine to lower cholesterol, medicine to treat depression, a phenothiazine medicine, a blood thinner (such as ticlopidine, warfarin), or stomach medicine.

Do not drink alcohol while you are using this medicine.

Warnings While Using This Medicine:

It is not safe to take this medicine during pregnancy. It could harm an unborn baby. Tell your doctor right away if you become pregnant.

Tell your doctor if you are breastfeeding, or if you have kidney disease, liver disease, diabetes, heart disease, low blood pressure, or porphyria.

This medicine may cause the following problems:

Serious skin reactions (may happen after treatment has stopped)

Drug reaction with eosinophilia and systemic symptoms (DRESS), which may damage organs such as the liver, kidney, or heart

Liver damage

Decreased levels of blood cells, which may cause bleeding or increase your risk for infection

Purple glove syndrome, which may damage skin and tissues near the injection site

Higher blood sugar levels

This medicine may make you dizzy or drowsy. Do not drive or do anything that could be dangerous until you know how this medicine affects you.

Tell any doctor or dentist who treats you that you are using this medicine. This medicine may affect certain medical test results.

Possible Side Effects While Using This Medicine:

Call your doctor right away if you notice any of these side effects:

Allergic reaction: Itching or hives, swelling in your face or hands, swelling or tingling in your mouth or throat, chest tightness, trouble breathing

Blistering, peeling, or red skin rash

Dark urine or pale stools, nausea, vomiting, loss of appetite, stomach pain, yellow skin or eyes

Fast, slow, or pounding heartbeat, lightheadedness or fainting

Fever, chills, cough, sore throat, and body aches

Fever, skin rash, or swollen glands in your armpits, neck, or groin

Pain, changes in skin color, sores, peeling, or swelling at or near the injection site

Severe confusion, problems with balance or walking, slurred speech, tremors

Unusual bleeding, bruising, or weakness

 [View Full Document](#)

 [Print](#)

Related Results

[Alternative Medicine
Disease
Toxicology](#)

[Drug Consults
Product Lookup - Tox & Drug](#)

查找痛風

GOUT



主頁

藥物
相互作用

IV 相容性

藥物
鑒定

藥物
比較

Tox 和藥物
產品查找

計算器

簡要解答

全部結果

Definition

Medical History

Findings

Differential Diagnosis

Testing

Treatment

Drug Therapy

Procedural Therapy

Non-Procedural Therapy

Reference

Testing

列印

Gout related to suspected hyperuricemia [2][3]

- Serum uric acid measurement: Serum uric acid levels have limited value for the diagnosis of gout; however, levels over 600 micromol/L increase the risk for developing gout [2][3].

Obtain a CBC during an initial evaluation to establish a baseline.

- Complete blood count

Suspected and known gout [4][5][6][7][8][9][10][11]

- Joint X-ray: Radiographic findings during initial gouty attacks may be normal, or may reveal soft tissue swelling. Late findings may include erosions, calcifications, and soft tissue nodules [5].

Suspected gout [12][13]

- Arthrocentesis: Joint aspiration for synovial fluid analysis is routinely recommended only in cases of suspected acute septic arthritis [12].

Suspected gout [4][14][15][16][17][18][19][20][21]

- Synovial fluid analysis: The presence of monosodium urate crystals in synovial fluid or tophus aspirate is definitively diagnostic for gout [4].

References ×

[2] Terkeltaub RA: Gout. N Engl J Med 2003; 349(17):1647-1655.

PubMed Abstract: <http://www.ncbi.nlm.nih.gov/...>

PubMed Article: <http://www.ncbi.nlm.nih.gov/...>

[Close](#)

Format: Abstract ▾ Send to ▾

N Engl J Med. 2003 Oct 23;349(17):1647-55.

Clinical practice. Gout.

Terkeltaub RA¹.




⊕ **Author information**

Comment in



Gout. [N Engl J Med. 2004]

PMID: 14573737 DOI: [10.1056/NEJMc030733](https://doi.org/10.1056/NEJMc030733)

[Indexed for MEDLINE] [Free full text](#)

Full text links

Save items ▲

Add to Favorites ▾

Similar articles ▲

Review Managing gout: there's more we can [J Fam Pract. 2014]

Gout

Quick Answers

All Results

Definition

Medical History

Findings

Differential Diagnosis

Testing

Treatment

Drug Therapy

Procedural Therapy

Non-Procedural Therapy

Reference

Treatment

 Print

Non-Procedural Therapy

Gout

- Local topical ice therapy

Gout

- Dietary and Lifestyle Recommendations

Related Results

Alternative Medicine

Drug

Toxicology

Gout

Quick Answers **In-Depth Answers** All Results

Background
Definition
Epidemiology
Etiology/ Pathophysiology
Complications

History And Physical
Summary
Medical History
Findings

Diagnostic Testing
Diagnostic Testing Summary
Tests

Diagnosis
Diagnostic Criteria
Differential Diagnosis

Treatment
Treatment Summary
Drug Therapy
Procedural Therapy
Non-Procedural Therapy

Related Information
Tests & Procedures

- Creatinine measurement, serum
- Lead mobilization test
- Serum uric acid measurement
- Synovial fluid analysis
- Thyroid stimulating hormone measurement
- Uric acid measurement, urine

[View Full Document](#)
[Print](#)

Related Results
[Alternative Medicine](#)
[Drug](#)
[Toxicology](#)

[Emergency Medical Abstracts](#)



[主頁](#)

[藥物
相互作用](#)

[IV 相容性](#)

[藥物
鑒定](#)

[藥物
比較](#)

[CareNotes®](#)

[NeoFax® / Pediatrics](#)

[其他工具](#) ▼

工具好幫手

藥物交互作用

搜尋 Micromedex



主頁

藥物
相互作用

IV 相容性

藥物
鑒定

藥物
比較

CareNotes®

NeoFax® / Pediatrics

其他工具 ▾

藥物相互作用

在搜尋欄位鍵入藥物名稱（品牌或學名藥）。選擇藥物並按一下 >（新

輸入搜尋詞：

Warfarin

相符的藥物名稱：(3)

Warfarin
Warfarin Sod
Warfarin Sodium

歐越莓/山桑子
/覆盆子

要檢查的藥物：

Bilberry
Calendula (Pot Marigold) •
Losartan Potassium
Warfarin

Add Allergies

金盞花

抗高血
壓藥物

帶有星號 (*) 的字母大寫項目表示過敏。

清除

提交

藥物相互作用

在搜尋欄位鍵入藥物名稱（品牌或學名藥）。選擇藥物並按一下 >（新增）按鈕。

輸入搜尋詞：

相符的藥物名稱: (3)

- Warfarin
- Warfarin Sod
- Warfarin Sodium

要檢查的藥物：

- Bilberry
- Calendula (Pot Marigold)
- Losartan Potassium
- Warfarin
- ASPIRIN*

Add Allergies



帶有星號 (*) 的字母大寫項目表示過敏。

清除

提交

取消

更新

Drug Interaction Results

← 修改相互作用






細化方式： 藥物： All 嚴重性： All 文件： All 類型： All

跳轉到： 藥物-藥物 (1) | 複方 (0) | 過敏症狀 (0) | 食物 (7) | 乙醇 (1) | 實驗室 (0) | 抽煙 (1) | 懷孕 (2) | 哺乳期 (2)

Drug-Drug 相互作用 (1)

藥物：	嚴重性：	文件：	綜述：
BILBERRY -- WARFARIN SODIUM	 Moderate	Fair	Concurrent use of BILBERRY and ANTICOAGULANTS may result in increased risk of bleeding.

定義
嚴重性：

-  **禁忌**
禁止同時使用這些藥物。
-  **嚴重**
這種相互作用可能危及生命和/或需要醫療干預以儘量減少或避免嚴重的不良影響。
-  **中等**
這種相互作用可能導致加重患者的病情和/或需要在治療中發生改變。
-  **較弱**
這種相互作用將限制臨床效果。表現可能包括增加副作用的頻率或嚴重程度，但一般不需要在治療中發生重大改變。
-  **未知**
未知。

Warfarin和歐越莓併用會增加出血風險

複方 (未找到)

Drug-過敏症狀 相互作用

Drug-食物 相互作用 (7)

藥物：	文件：	綜述：
WARFARIN SODIUM	Good	Concurrent use of WARFARIN and POMEGRANATE may result in increased warfarin plasma concentrations and increased risk of bleeding.

INTERACTION DETAIL

Warning:

Concurrent use of BILBERRY and ANTICOAGULANTS may result in increased risk of bleeding.

Clinical Management:

Caution is advised if bilberry is taken with an anticoagulant. Monitor the patient closely for signs and symptoms of bleeding. Adjust the anticoagulant dose only if the patient is consistently taking bilberry with a consistent and standardized product.

Onset:

Delayed

Severity:

Moderate

Documentation:

Fair

INTERACTION DETAIL

Probable Mechanism:

additive antiplatelet effects

Summary:

Theoretically, bilberry may potentiate the effects of anticoagulants. One case report describes a patient taking several herbal medicines including bilberry (*Vaccinium myrtillus* (VMA)) who developed substantial postoperative bleeding (Norred & Finlayson, 2000). Oral doses of VMA (Myrtocyan®), inhibited platelet aggregation in humans (Pulliero et al, 1989). VMA inhibited platelet aggregation and prolonged bleeding time in rabbits (Morazzoni & Magistretti, 1990). VMA increased production of prostaglandin I₂-like substances in vascular tissues in rats, leading to enhanced anti-aggregatory mechanisms (Morazzoni & Magistretti, 1986).

Literature:

A 60-year-old female taking several undisclosed dietary supplements up to the day of surgery (left modified radical mastectomy with sentinel node biopsy and right breast reduction) experienced substantial postoperative bleeding. Herbal supplements included bilberry, ginkgo, huang qi (astragalus), and ginseng. Vitamin supplements included vitamin E, vitamin C, and vitamin B12. Prescription medications included montelukast, albuterol, salmeterol, fluticasone, quinine, and sertraline. Preoperative labs were normal except for a slightly prolonged prothrombin time of 15.6 seconds (reference range, 10.2 to 12.3 seconds), and INR 1.27 (normal 1). The patient and surgeons

列印  關閉 

Drug Interaction Results

修改相互作用

細化方式： 藥物： All 嚴重性： 2 (Selected) 文件： All 類型： All

跳轉到： 食物 (2) | 懷孕 (2) | 哺乳期 (1)

選中/取消選中以細化嚴重性設定。

全部選中 | 全部不選

- Contraindicated
- Major
- Moderate
- Minor
- Unknown

取消 更新

Drug-食物 相互作用 (2)

藥物：	嚴重性：	文件：	綜述：
WARFARIN SODIUM	 Major	Good	Concurrent use of WARFARIN and POMEGRANATE may result in increased warfarin plasma concentrations and increased risk of bleeding.
WARFARIN SODIUM	 Major	Good	Concurrent use of WARFARIN and CRANBERRY JUICE may result in an increased risk of bleeding.

Drug-懷孕 相互作用 (2)

藥物：	嚴重性：	文件：	綜述：
WARFARIN SODIUM	 Contraindicated	Unknown	Warfarin is rated as US FDA Category X. Studies, adequate well-controlled or observational, in animals or pregnant women have demonstrated positive evidence of fetal abnormalities. The use of the product is contraindicated in women who are or may become pregnant.
LOSARTAN POTASSIUM	 Major	Unknown	Losartan is rated as US FDA Category D. Studies, adequate well-controlled or observational, in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy may outweigh the potential risk.

Drug-哺乳期 相互作用 (1)

藥物：	嚴重性：	文件：	綜述：
LOSARTAN POTASSIUM	 Major	Unknown	Infant risk cannot be ruled out. Available evidence and/ or expert consensus is inconclusive or is inadequate for determining infant risk when Losartan is used during breast-feeding. Weigh the potential benefits of treatment against potential risks before prescribing Losartan during breast-feeding.

定義

嚴重性：	 禁忌	 嚴重	 中等	 較弱	 未知
文件：	卓越	良好	一般	未知	



延伸問題

市面上含**鉀**的食品越來越多，有哪些藥物是藥師特別要注意，提醒病患用藥時多注意的呢？

多個藥物的IV相容性

The screenshot shows the IV Compatibility tool interface. At the top, a navigation bar includes '主頁', '藥物相互作用', 'IV 相容性' (highlighted with a red box), '藥物鑒定', '藥物比較', 'CareNotes®', and 'NeoFax® / Pediatric'. Below the navigation bar, the title 'IV 相容性' is displayed. A search instruction reads: '在搜尋欄位鍵入藥物名稱 (品牌或學名藥)。選擇藥物並按一下 (新增) 按鈕。' Below this is a search input field containing 'pal'. Underneath, '相符的藥物名稱: (2)' lists 'Palifermin' and 'Palonosetron hydrochloride'. To the right, '要檢查的藥物:' contains 'Lorazepam'. At the bottom of the interface are '清除' and '提交' buttons. Two blue callout bubbles are present: one pointing to the 'IV 相容性' menu item with the text '適用於焦慮狀態', and another pointing to 'Palonosetron hydrochloride' with the text '化療用藥'.

由 Trisnel's™ 2 Clinical Pharmaceuticals Database (Parenteral Compatibility). 支援。

IV 索引包含 BAXTER HEALTHCARE CORPORATION 的機密資訊。嚴格禁止明確的被許可人之外的人員使用 IV 索引或其中包含的資訊。



IV 相容性結果

← 修改相容性



Key:

相容性: All ▾

All Drugs (2)

全部選中 | 全部不選

- Lorazepam
- Palonosetron hydrochloride

取消 更新

Tip: To see additional information on IV Solutions and TPN/TNA compatibility, select a single drug from the list and choose Update.

Y-Site

Admixture

Syringe

Y-Site Test Detail

Rating

Lorazepam - Palonosetron hydrochloride



相容

IV COMPATIBILITY DETAIL

Drug 1	Drug 2	狀態	資訊	測試參數
Lorazepam 0.5mg/mL in 0.5% D5W-Dextrose 5% Baxter Pharmaceutical Products	Palonosetron hydrochloride 0.05mg/mL (50 mcg/mL) in Undiluted MGI Pharma	 相容	物理相容性: Physically compatible. No visible changes and no change in the measured haze level or particulates. 化學穩定性: Chemically stable. No loss of either drug occurred within the study period. 存放: Ambient conditions of about 23 °C exposed to normal fluorescent light.	參考: : 2608 試驗期: 4 hours. 方法: Visual observation, electronic measurement of haze and particulates, and stability-indicating HPLC analysis of drug concentrations. 容器: Simulated Y-site administration using glass test tubes.

由 Trissel's™ 2 Clinical Pharmaceutics Database (Parenteral Compatibility). 支援。

IV索引包含 BAXTER HEALTHCARE CORPORATION 的機密資訊。嚴格禁止明確的被許可人之外的人員使用 IV索引或其中包含的資訊。

單一藥物的IV相容性

IV 相容性結果 ← 修改相容性

列印

Selected Drug: Palonosetron hydrochloride

Key:

相容性: All ▾

All Drugs (2)

全部選中 | 全部不選

- Lorazepam
- Palonosetron hydrochloride

取消 更新



Solution	Y-Site	Admixture	Syringe	TPN/TNA		
Common Solutions Test Detail						
D5W (D5W-Dextrose 5%)					相容	More Solution Information
D10W (Dextrose 10%)					未測試	
D5LR (Dextrose 5% in lactated Ringers)					相容	More Solution Information
D5NS (Dextrose 5% in sodium chloride 0.9%)					未測試	
D5W - 1/2 NS (Dextrose 5% in sodium chloride 0.45%)					相容	More Solution Information
NS (Normal saline- Sodium chloride 0.9%)					相容	More Solution Information
1/2 NS (Sodium chloride 0.45%)					未測試	

Other Solutions Test Detail	Rating	Solution Information
-----------------------------	--------	----------------------

Calculators

Home	Drug Interactions	IV Compatibility	Drug ID	Drug Comparison	CareNotes®	NeoFax® / Pediatrics	Other Tools ▼
----------------------	-----------------------------------	----------------------------------	-------------------------	---------------------------------	----------------------------	--------------------------------------	-------------------------------

Calculators

View: [by category](#) | [by alphabetical list ▶](#)

ANTIDOTE DOSING AND NOMOGRAMS

- [Alcohols/Ethylene Glycol Blood Level](#)
- [Ethanol - IV Dosing for Methanol/Ethylene Glycol Overdose](#)
- [NAC Dosing for Acetaminophen Overdose](#)
- [Toxicity Nomograms](#)

LABORATORY VALUES

- [Anion Gap Calculator](#)
- [Creatinine Clearance Calculator](#)
- [Phenytoin Level Adjustment Calculator](#)

DOSING TOOLS

- [ACLS/PALS Guidelines](#)
- [Dobutamine Dosing Calculator](#)
- [Dopamine Dosing Calculator](#)
- [Epinephrine Dosing Calculator - Adult](#)
- [Epinephrine Dosing Calculator - Pediatric](#)
- [Heparin Dosing Calculator](#)
- [IV Rate Calculator](#)
- [Nitroglycerin Dosing Calculator](#)
- [Nitroprusside Dosing Calculator](#)
- [Norepinephrine Dosing Calculator - Adult](#)
- [Norepinephrine Dosing Calculator - Pediatric](#)

CLINICAL CALCULATORS

- [Alveolar-Arterial Oxygen Gradient](#)

MEASUREMENT CALCULATORS

- [Body Mass Index Calculator](#)
- [BSA and Lean/Ideal Body Weight Calculator](#)
- [Metric Conversions Calculator](#)
- [SIU Conversion Calculator](#)

Select Dosing Type: Pediatric Adult

Patient Weight: kg lb

[Calculator Help](#)

Results: [Thu May 25 01:08:38 GMT 2017]

Pediatric Emergency Drug Dosing Calculator

Caution: Using pediatric dosing for weight greater than 50 kg

This calculator is intended to calculate dosing for pediatric patients aged 29 days or older; it is not intended for dosing of neonates. As with all MICROMEDEX products, please use caution and exercise your clinical discretion and professional judgment when utilizing this calculator.

Thu May 25 01:08:38 GMT 2017

Patient Name:

Entered Values: Dosing Type: **Pediatric** Patient Weight: 60 kg (132 lb)

Recommendations according to AHA guidelines ACLS/PALS resuscitation.

**Attention - Institutionally dispensed drug concentrations may vary.*

Drug	Route	Dose	Delivery
Adenosine			
Initial: 0.1 mg/kg/dose	Rapid IV/IO Push	6 mg/dose (2 mL/dose of 3 mg/mL conc)	Immediately follow drug administration with at least 5 mL normal saline.
MAX: 6 mg/dose		MAX: 6 mg/dose	
Repeat: 0.2 mg/kg/dose		Repeat: 12 mg/dose (4 mL/dose of 3 mg/mL conc)	
MAX: 12 mg/dose		MAX: 12 mg/dose	
Amiodarone			

Select Dosing Type: Pediatric Adult

Patient Weight: kg lb

[Calculator Help](#)

Results: [Thu May 25 01:26:07 GMT 2017]

Adult Emergency Drug Dosing Calculator

Thu May 25 01:26:07 GMT 2017

Patient Name:

Entered Values: Dosing Type: **Adult** Patient Weight: 60 kg (132 lb)

Recommendations according to AHA guidelines ACLS/PALS resuscitation.

**Attention - Institutionally dispensed drug concentrations may vary.*

Drug	Route	Dose	Delivery
Adenosine			
6 mg May Repeat: 12 mg X 2 MAX: 30 mg	Rapid IV Push	6 mg (2 mL of 3 mg/mL conc) over 1 to 3 seconds May Repeat: after 1 to 2 minutes, 12 mg (4 mL of 3 mg/mL conc) over 1 to 3 seconds; may repeat another 12 mg after 1 to 2 minutes MAX: 30 mg	Follow adenosine IV push with 20 mL saline flush. Higher doses may be required in patients taking theophylline.
Amiodarone: Cardiac Arrest			
300 mg May Repeat: 150 mg x 1	IV Push/IO	300 mg (6 mL of a 50 mg/mL conc) May Repeat: 150 mg (3 mL of a 50 mg/mL conc) x 1	Dilute in 20 to 30 mL of D5W or may administer undiluted.

中草藥/保健食品



碩睿資訊有限公司
Shou Ray Information Service Co., Ltd.

靈芝_Indication

CORIOLUS VERSICOLOR



[主頁](#)

[藥物
相互作用](#)

[IV 相容性](#)

[藥物
鑒定](#)

[藥物
比較](#)

[CareNotes®](#)

[NeoFax® / Pediatrics](#)

[其他工具](#) ▼

Coriolus Versicolor

簡要解答

深入解答

全部結果

Name Info

Class

Dosing & Indications

Adult Dosing

Indications

Contraindications/ Warnings

Contraindications

Pregnancy Category

Lactation

Drug Interactions (single)

Adverse Effects

Administration

How Supplied

Dosing & Indications

Indications

請參閱 ['深入解答'](#) 瞭解詳細結果。

- antioxidant (animal data)
- cancer
- cancer chemotherapy adjunct
- immune response



列印

相關結果

- [Product Lookup - Martindale](#)
- [Product Lookup - Tox & Drug](#)

靈芝_Adverse Reactions

Coriolus Versicolor

簡要解答

深入解答

全部結果

Overview

Dosing Information

Dosage Forms

Storage And Stability

Adult Dosage

Pediatric Dosage

Pharmacokinetics

Drug Concentration Levels

Adme

Cautions

Contraindications

Adverse Reactions

Teratogenicity/ Effects In Pregnancy

Drug Interactions

Cautions

Adverse Reactions

 檢視完整文件

 列印

BLOOD

BLOOD EFFECTS

1) In a trial administering PSK, a protein-bound polysaccharide from *Coriolus versicolor*, to patients (n=448) receiving standard chemotherapy (mitomycin C and 5-fluorouracil) for colorectal cancer, more patients receiving PSK with chemotherapy experienced leukopenia resulting in abbreviated treatment than those receiving chemotherapy alone. In the group receiving chemotherapy alone, 2 patients (0.9%) had leukopenia for which treatment was abbreviated while 7 patients in the PSK group (3.2%) had such leukopenia (Mitomi et al, 1992).

GASTROINTESTINAL

GASTROINTESTINAL EFFECTS

1) Oral administration of PSP, a group of polysaccharide peptides from *Coriolus versicolor*, was frequently associated with the passage of dark colored stools. No blood was detected with fecal occult blood tests (Shiu et al, 1992).

2) In a trial administering PSK, a protein-bound polysaccharide from *Coriolus versicolor*, to patients receiving standard chemotherapy (mitomycin C and 5-fluorouracil) for colorectal cancer, more patients receiving PSK with chemotherapy experienced DIARRHEA resulting in abbreviated treatment than those receiving



Q & A

Thank You!

客服中心

服務專線：02-7731-5800

服務傳真：02-8226-5022

客戶服務信箱：

services@customer-support.com.tw

專人服務時間：週一～週五 9:00~17:30

系統服務時間：全年無休